XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer
Qingwu Du, Tingting Qin, Jingya Wang, Yantao Jiang, Qi Xu, Xueyang Li, Huiyan Liu, Junjie Yu, Yi Lu, Luyao Tong, Tao Sun, Peng Chen, Richeng Jiang, Dingzhi Huang · 2026
Read XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer by Qingwu Du, Tingting Qin, Jingya Wang, Yantao Jiang, Qi Xu, Xueyang Li, Huiyan Liu, Junjie Yu, Yi Lu, Luyao Tong, Tao Sun, Peng Chen, Richeng Jiang, Dingzhi Huang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13594258.txt.
Description
Qingwu Du and thirteen co-authors report a 2026 study on why small cell lung cancer shrugs off immune therapy. This fast cancer builds a suppressive shield of immune cells around itself. Working with mouse tumors and patient samples, the team traced the shield to a shipping protein that moves cargo out of the cell nucleus.
That shipper expels a second protein, which then orders the shredding of a defender that would raise an immune alarm call. With the call silenced, guard cells drift into a state that blinds tumor cells to attack. Blocking the shipper restored the alarm, curbed the guard drift, and made a standard immune drug work far better in mice. The authors propose the pair as a joint drug target.
Catalog record
| CREATOR | Qingwu Du, Tingting Qin, Jingya Wang, Yantao Jiang, Qi Xu, Xueyang Li, Huiyan Liu, Junjie Yu, Yi Lu, Luyao Tong, Tao Sun, Peng Chen, Richeng Jiang, Dingzhi Huang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 92 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |